• Dysregulated gene expression confers malignant phenotype to the cells. • Overexpression of oncogenic and mutant proteins is most often reported in OSCC. • Targeted protein degradation can be developed as an effective therapeutic modality to degrade these proteins.
No takes yet. Share an insight, caveat, or question.
Pandi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: